🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

UPDATE ‼️ Future of breast cancer screening ⁉️ #bcsm

UPDATE FROM MA.32 trial ‼️ Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

The longest follow up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study was still alive. academic.oup.com/oncolo/advance… How to recognize & increase the rate of long-term survivors? 👉 jamanetwork.com/journals/jamao…

Healio spoke with Ann Partridge MD, MPH in this exclusive cover story regarding data that shows the overwhelming majority of new breast cancer diagnoses for women occur after the age of 40. Therefore, younger woman are underrepresented in clinical trials. bit.ly/3Zt8y5T

🍂Jane Lowe Meisel, MD Dionisia Quiroga, DO, PhD, FASCO are finalizing the upcoming #BCSM #TumorBoardTuesday for 10/03 🌴Join at 8pm ET to discuss CDK4/6i treatment options & breaking updates to ADC use in those with HR+/HER2- met #BreastCancer 🏝️FREE #CME 👉🏽integrityce.com/TBT2023👈🏼

Mark your calendar to join this #BCSM #TumorBoardTuesday 👆🏽 Stephanie Graff, MD, FACP, FASCO Matteo Lambertini, MD PhD IR Yakup Ergün Nagi El Saghir MD, FASCO, FACP Yara Abdou, MD, MSCR Biagio Ricciuti, MD PhD Maryam Lustberg MD, MPH, FASCO Eric Winer, MD Dr. Anselmo Bertetti Paula Cabrera Demetria Smith-Graziani, MD, MPH Sara Tolaney Deniz Can Guven Alan Reyes-M.D John Haanen

Yeees❗️ Put this in your calendar 📅 Make sure to keep yourself updated‼️

Drug repurposing is great. The results from the MA.32 trial should discourage further investigation of metformin as an addition to adjuvant treatment of breast cancer patients…🛑 #bcsm

UPDATE‼️ Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial | Journal of Clinical Oncology ‼️ ascopubs.org/doi/full/10.12…

UPDATE - OBESITY & BREAST CANCER RECURRENCE‼️ This study suggests that obesity is associated with an increased risk of recurrence among patients with hormone receptor–positive breast cancer treated with aromatase inhibitors‼️ jamanetwork.com/journals/jaman…

BEGONIA: Dato-DXd + Durvalumab in mTNBC update ORR 79% mPFS 13.8 mo >80% with low PDL1 expression (by SP263 or 22C3) Can IO lead to benefit even in PDL1- tumors when combined with a potent ADC? #ESMO23 OncoAlert #bcsm

⭐️Dr. Paolo Tarantino discusses the large improvement in pathological complete response w/chemo immunotherapy for high risk HR+ Stage 2/3 breast cancer. We also talk about the use of CDK4 inhibitor and PD inhibitor after surgery. #ESMO23 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 #OncLiveTakeOver Paolo Tarantino

🚨After Neoadj chemo for cT1-2N0-1M0 TNBC or HER2+ BC, this trial used core biopsy to confirm pCR. Pts were then tx w/ RT alone WITHOUT breast surgery Biopsy=pCR in 31/50 patients ‼️3-year ipsilateral breast tumour recurrence (IBTR) rate = 0% and 3-yr DFS and OS =100% #ESMO23

UPDATE ‼️

📈 Highly cited paper (2022): "Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice" by Dr. Sean Hacking and Dr. Yihong Wang (Brown University Pathology Residents & Fellows Brown Pathology and Laboratory Medicine). 🔗 Read more: xiahepublishing.com/2771-165X/JCTP… 👥 Chinese American Pathologists Association Guoping Cai, MD Breast Cancer Research Updates Elisa Agostinetto

New Journal of Clinical Oncology🗞️| RCT of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With #BreastCancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Tara Sanft #JenniferLigibel Dawn Hershman 👉pubmed.ncbi.nlm.nih.gov/37656930/

UPDATE ALERT‼️ Read!👇

A very interesting review🙌🏻😱 on the complex relationship between diabetes and breast cancer raises crucial considerations in treatment decisions, especially in women with comorbidities. The review 🕵🏻highlights the undeniable connection between diabetes and an increased risk of

#ESMOBreast24 #ESMOAmbassadors 🔑🚫Primary outcome in IMpassion132 highlights unmet need for early relapsing #TNBC 🔑Emerging data from ADC-IO combinations 🔑Safety and #QoL updates for new 💊capivasertib and 💉datopotamab 🔑📈Body of evidence for new biomarkers 🎯such as HER2Dx

Top #ASCO24 picks in breast #bcsm oncology! Exciting! Next week! OncoAlert Sarah Cannon Docs ESMO - Eur. Oncology